放疗联合免疫治疗复发性食管癌的疗效及对T淋巴细胞、肿瘤标志物的影响OACSTPCD

Objective To investigate the efficacy of radiotherapy combined with Paporizumab in the treatment of recurrent esophageal cancer and its effect on T lymphocytes and tumor markers.Methods Thirty-three patients with recur-rent esophageal cancer who underwent three-dimensional conformal intensity-modulated radiotherapy(IMRT)in the Depart-ment of Thoracic and Abdominal Radiotherapy,Affiliated Tumor Hospital of Xinjiang Medical University from September 2020 to September 2023 were selected as the control group,and 33 patients with recurrent esophageal cancer who under-went IMRT combined with carrelizumab in the same period were selected as the observation group.Both groups were trea-ted for 6 weeks,and then the clinical efficacy of the patients was evaluated.Both groups were treated for 6 weeks,and the clinical efficacy of the patients was evaluated at 6 weeks of treatment.T lymphocyte subsets[CD3 cells(CD3+),CD4 cells(CD4+),CD8 cells(CD8+)],tumor proliferation-related factors[vascular endothelial growth factor(VEGF),matrix metallopro-teinase-9(MMP-9),transcription factor Yin and Yang 1(YY1)],tumor markers[carbohydrate antigen 125(CA125),carcino-embryonic antigen(CEA),squamous cell carcinoma antigen(SCC)]were compared between the two groups before treatment and 6 weeks after treatment.The occurrence of toxic and side effects during treatment was recorded and compared between the two groups.Results After treatment,the total effective rate of the observation group[96.97％(32/33)]was higher than that of the control group[75.76％(25/33)](x2/P=4.632/0.031).After treatment,VEGF,MMP-9,YY1,CA125,CEA and SCC in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(t/P=4.598/＜0.001,3.317/＜0.001,4.664/＜0.001).After treatment,CD8+was lower than that in the control group,CD3+and CD4+in the observation group were significantly higher than those in the control group(x2/t/P=7229/＜0.001,6.388/＜0.001,6.157/＜0.001,5.322/＜0.001,5.116/＜0.001,2.479/0.016).During the treatment,the incidence of toxic and side effects in the two groups was compared(x2/P=0.471/0.492).Conclusion Radiotherapy combined with Pablizumab can more effectively reduce the levels of tumor proliferation-related factors and tumor markers,improve the clinical efficacy,im-prove the immune function of patients,and will not significantly increase the risk of toxic and side effects.